PMID- 37559065
OWN - NLM
STAT- MEDLINE
DCOM- 20230811
LR  - 20231123
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Aug 10
TI  - Berberine-loaded albumin nanoparticles reverse aflatoxin B1-induced liver 
      hyperplasia.
PG  - 42
LID - 10.1186/s40360-023-00683-w [doi]
LID - 42
AB  - Hepatocellular carcinoma (HCC) can be produced from aflatoxin B1 (AFB1) 
      administration. Although berberine (BER) acts as an anticancer agent and can 
      counteract the AFB1 effect, it has low bioavailability. Nanotechnology can 
      overcome this problem. This research aimed to synthesize berberine nanoparticles 
      (NPs) and then estimate their therapeutic effect compared to that of berberine 
      against aflatoxin-induced hepatotoxicity. The desolvation method was used to 
      prepare BER-NPs. Aflatoxicosis was induced by 5 consecutive intraperitoneal 
      injections (IP) of 200 microg/kg/day AFB dissolved in dimethylsulfoxide (DMSO). After 
      the induction period, two treatments were performed: the first with 100 mg/kg BER 
      and the second with 10 mg/kg BER-NPs. Liver, kidney, and diabetic profiles were 
      estimated by using standardized methods. Hepatic oxidative stress, inflammatory, 
      cancer cell proliferation, and invasion markers were used by ELISA and qPCR 
      techniques. The TEM image shows that both BSA NPs and BER-BSA NPs had spherical, 
      regular, and uniform shapes. The BER encapsulation efficiency % was 78.5. The 
      formed-BER-BSA NPs showed a loading capacity % of 7.71 and the synthesis yield % 
      of 92.6. AFB1 increases pro-oxidant markers, decreases antioxidant systems, 
      stimulates inflammatory enzymes, inhibits anti-inflammatory markers, decreases 
      tumor suppressor enzymes, increases oncogenes, increases glycolytic activity, 
      prevents cell death, and promotes cell growth. Most of the biochemical markers 
      and hepatic architecture were normalized in the BER-BSA NP-treated group but not 
      in the BER-treated group. Altogether, the obtained data proved that treatment 
      with BER-NPs was more efficient than treatment with berberine against 
      aflatoxicoses induced in rats.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Khedr, Sarah M
AU  - Khedr SM
AD  - Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 
      11566, Egypt.
FAU - Ghareeb, Doaa A
AU  - Ghareeb DA
AUID- ORCID: 0000-0003-3327-4377
AD  - Bio-Screening and Preclinical Trial Lab, Department of Biochemistry, Faculty of 
      Science, Alexandria University, Alexandria, Egypt. d.ghareeb@alexu.edu.eg.
FAU - Fathy, Shadia A
AU  - Fathy SA
AD  - Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 
      11566, Egypt.
FAU - Hamdy, Germine M
AU  - Hamdy GM
AD  - Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 
      11566, Egypt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230810
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 9N2N2Y55MH (Aflatoxin B1)
RN  - 0I8Y3P32UF (Berberine)
RN  - 0 (Albumins)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Carcinoma, Hepatocellular/chemically induced/drug therapy/pathology
MH  - *Liver Neoplasms/chemically induced/drug therapy/pathology
MH  - Aflatoxin B1/toxicity
MH  - *Berberine/pharmacology/therapeutic use
MH  - Hyperplasia/drug therapy
MH  - Albumins/therapeutic use
MH  - *Nanoparticles
PMC - PMC10413506
OTO - NOTNLM
OT  - Apoptosis
OT  - Arginase-1
OT  - Cell death
OT  - Cyclooxygenase-2
OT  - Desolvation method
OT  - Insulin growth factor 2
COIS- The authors declare no competing interests.
EDAT- 2023/08/10 00:42
MHDA- 2023/08/11 06:42
PMCR- 2023/08/10
CRDT- 2023/08/09 23:38
PHST- 2022/12/03 00:00 [received]
PHST- 2023/08/01 00:00 [accepted]
PHST- 2023/08/11 06:42 [medline]
PHST- 2023/08/10 00:42 [pubmed]
PHST- 2023/08/09 23:38 [entrez]
PHST- 2023/08/10 00:00 [pmc-release]
AID - 10.1186/s40360-023-00683-w [pii]
AID - 683 [pii]
AID - 10.1186/s40360-023-00683-w [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2023 Aug 10;24(1):42. doi: 10.1186/s40360-023-00683-w.